The University of Southampton
University of Southampton Institutional Repository

Conjugated linoleic acid and human health-related outcomes

Conjugated linoleic acid and human health-related outcomes
Conjugated linoleic acid and human health-related outcomes
There has been increasing interest in health benefits of conjugated linoleic acid (CLA) based on findings with laboratory animals. Some human studies have also suggested health benefits of CLA, but because of the mixes used these could not be readily associated with a particular isomer of CLA. A recent study examined the separate effects of near-pure cis-9,trans-11 CLA (c9,t11 CLA) or trans-10,cis-12 CLA (t10,c12 CLA) on health-related outcomes in healthy young males. The CLA isomers were provided in capsules and at three doses (up to about 2.5 g/day) each for 8 weeks. Both c9,t11 and t10,c12 CLA were incorporated in a dose–response fashion into blood lipids and cells. At the doses and durations used, neither isomer of CLA affected bodyweight, body mass index or body composition, insulin sensitivity, immune function or markers of inflammation. However, at the doses and durations used, c9,t11 and t10,c12 CLA had opposing effects on blood lipid concentrations. Altered dairy cow-feeding practices were used to produce c9,t11 CLA-rich milk and, from this ultra heat-treated milk, cheese and butter were produced. The milk and the dairy products made from it had ninefold higher contents of c9,t11 CLA, higher contents of n-3 fatty acids and lower contents of total fat and of saturated fatty acids. They also contained much higher contents of trans-vaccenic acid (tVA). The modified dairy products were used in a 6-week controlled dietary intervention study in healthy middle-aged males. c9,t11 CLA and tVA were incorporated from dairy products into blood lipids and cells. Consumption of the CLA-rich (and tVA-rich) dairy products did not affect bodyweight or body mass index, insulin sensitivity or inflammatory markers. However, there were some detrimental effects on blood lipids. These effects may be due to tVA rather than to c9,t11 CLA, as they are consistent with the effects of trans fatty acids and not consistent with the effects of c9,t11 CLA identified in the earlier study with c9,t11 CLA in capsules.
human, linoleic acid, acid, conjugated linoleic acid
0141-9684
93-99
Yaqoob, P.
eb74426f-4486-41ca-bb29-2e3ce3e65b68
Tricon, S.
e0b47f13-a8b7-43be-8043-4df155713c8d
Williams, C.M.
9e4a42ff-e3e9-4f40-9343-a3a1625c7bbd
Grimble, R.F.
3100e4d2-8f29-4ca6-a95d-38a6a764865f
Burdge, G.C.
09d60a07-8ca1-4351-9bf1-de6ffcfb2159
Calder, P.C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Yaqoob, P.
eb74426f-4486-41ca-bb29-2e3ce3e65b68
Tricon, S.
e0b47f13-a8b7-43be-8043-4df155713c8d
Williams, C.M.
9e4a42ff-e3e9-4f40-9343-a3a1625c7bbd
Grimble, R.F.
3100e4d2-8f29-4ca6-a95d-38a6a764865f
Burdge, G.C.
09d60a07-8ca1-4351-9bf1-de6ffcfb2159
Calder, P.C.
1797e54f-378e-4dcb-80a4-3e30018f07a6

Yaqoob, P., Tricon, S., Williams, C.M., Grimble, R.F., Burdge, G.C. and Calder, P.C. (2006) Conjugated linoleic acid and human health-related outcomes. Nutrition Bulletin, 31 (2), 93-99. (doi:10.1111/j.1467-3010.2006.00560.x).

Record type: Review

Abstract

There has been increasing interest in health benefits of conjugated linoleic acid (CLA) based on findings with laboratory animals. Some human studies have also suggested health benefits of CLA, but because of the mixes used these could not be readily associated with a particular isomer of CLA. A recent study examined the separate effects of near-pure cis-9,trans-11 CLA (c9,t11 CLA) or trans-10,cis-12 CLA (t10,c12 CLA) on health-related outcomes in healthy young males. The CLA isomers were provided in capsules and at three doses (up to about 2.5 g/day) each for 8 weeks. Both c9,t11 and t10,c12 CLA were incorporated in a dose–response fashion into blood lipids and cells. At the doses and durations used, neither isomer of CLA affected bodyweight, body mass index or body composition, insulin sensitivity, immune function or markers of inflammation. However, at the doses and durations used, c9,t11 and t10,c12 CLA had opposing effects on blood lipid concentrations. Altered dairy cow-feeding practices were used to produce c9,t11 CLA-rich milk and, from this ultra heat-treated milk, cheese and butter were produced. The milk and the dairy products made from it had ninefold higher contents of c9,t11 CLA, higher contents of n-3 fatty acids and lower contents of total fat and of saturated fatty acids. They also contained much higher contents of trans-vaccenic acid (tVA). The modified dairy products were used in a 6-week controlled dietary intervention study in healthy middle-aged males. c9,t11 CLA and tVA were incorporated from dairy products into blood lipids and cells. Consumption of the CLA-rich (and tVA-rich) dairy products did not affect bodyweight or body mass index, insulin sensitivity or inflammatory markers. However, there were some detrimental effects on blood lipids. These effects may be due to tVA rather than to c9,t11 CLA, as they are consistent with the effects of trans fatty acids and not consistent with the effects of c9,t11 CLA identified in the earlier study with c9,t11 CLA in capsules.

This record has no associated files available for download.

More information

Published date: 2006
Keywords: human, linoleic acid, acid, conjugated linoleic acid

Identifiers

Local EPrints ID: 61626
URI: http://eprints.soton.ac.uk/id/eprint/61626
ISSN: 0141-9684
PURE UUID: d0d049f4-f5f6-4137-a0ee-229c9df40f28
ORCID for G.C. Burdge: ORCID iD orcid.org/0000-0002-7665-2967
ORCID for P.C. Calder: ORCID iD orcid.org/0000-0002-6038-710X

Catalogue record

Date deposited: 09 Sep 2008
Last modified: 16 Mar 2024 02:51

Export record

Altmetrics

Contributors

Author: P. Yaqoob
Author: S. Tricon
Author: C.M. Williams
Author: R.F. Grimble
Author: G.C. Burdge ORCID iD
Author: P.C. Calder ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×